06.03.2013 14:20 Uhr, Quelle: Wallstreet online

FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

CONCERTO Study Enrolling Patients Globally to Evaluate Impact of Laquinimod on Disability Progression Jerusalem, Israel and Lund, Sweden, March 6, 2013 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) …

Weiterlesen bei Wallstreet online